Pharmafile Logo
Pharmafocus logo
Advanced Search

Repatha

Showing 15 posts of 18 posts found.

shutterstock_274590824

Jury upholds Amgen’s patent validity for Repatha, deflecting challenge from Sanofi and Regeneron

February 26, 2019
Manufacturing and Production, Sales and Marketing Amgen, Regeneron, Repatha, Sanofi, patent, pharma

Amgen is celebrating after a Delaware jury backed the validity of two of its patents against challenges from Regeneron and …

News
amgen_flag

China’s NMPA approves Amgen’s Repatha to reduce cardiovascular event risk

January 25, 2019
Medical Communications, Sales and Marketing Amgen, China, Repatha, cardiovascular disease, pharma, stroke

Amgen has announced that its proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor Repatha (evolocumab) has secured approval by China’s drug …

News
amgen_hq

Amgen slashes price of cholesterol drug Repatha by 60%

October 25, 2018
Sales and Marketing Repatha, cholestrol, drug, medicine, pricing

American multinational Amgen has slashed the price of cholesterol drug Repatha, reducing the medication’s US list price by 60%. The …

News
amgen_hq

Europe expands approved indication of Amgen’s Repatha in cardiovascular disease

May 17, 2018
Sales and Marketing Amgen, Repatha, cardiovascular disease, pharma

Amgen has revealed that its PCSK9 inhibitor Repatha (evolocumab) has received approval from the European Commission in a new indication: …

News

Sanofi & Regeneron deflect Amgen’s legal marketing block on Praluent

February 9, 2017
Manufacturing and Production, Sales and Marketing Amgen, Regeneron, Repatha, Sanofi, praluent

Sanofi and Regeneron have successfully won in a US Court ruling calling for the suspension of the permanent injunction of …

News
amgen_hq

Positive Phase III results for Amgen’s Repatha for coronary artery disease

September 21, 2016
Research and Development Amgen, Phase III trial, Repatha

Amgen has announced that its monoclonal antibody Repatha (evolocumab) achieved positive Phase III results for the treatment of coronary artery …

News
praluent_75mg_pen_box_hr

Amgen, Sanofi cholesterol medicines “not cost-effective”, need to drop price by two-thirds

August 17, 2016
Research and Development, Sales and Marketing Amgen, QALY, Regeneron, Repatha, Sanofi, cost effective, cost-effective, praluent

A new study published in JAMA has suggested that Amgen, Sanofi and Regeneron would have to reduce their prices for …

News
amgen_flag

FDA approves single monthly injection of Amgen’s Repatha

July 12, 2016
Manufacturing and Production, Sales and Marketing Amgen, FDA, Repatha, pushtronex

Amgen (NASDAQ: AMGN) has announced that the US Food and Drug Administration (FDA) has approved a new, monthly single-dose administration …

News

NICE recommends Sanofi, Amgen cholesterol drugs

May 6, 2016
Medical Communications, Sales and Marketing Amgen, Draft Guidance, NHS, NICE, Repatha, Sanofi, cardiovascular disease, cholesterol, final draft guidance, high cholesterol, praluent, recommendation, treatment

The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending two new drugs for the …

News
amgen_flag

Amgen’s high cholesterol drug at centre of patent court case yields positive clinical trial results

April 4, 2016
Research and Development, Sales and Marketing Amgen, Repatha, Sanofi, high cholesterol. ldl, ldl-c, phase III, statins

Amgen has announced positive results from the Phase III GAUSS-3 clinical trial evaluating Repatha (evolucumab) in patients with high cholesterol …

News
amgen_sign_on_wall

Amgen wins high-profile cholesterol drug patent case v Sanofi

March 17, 2016
Sales and Marketing Amgen, PCSK9, Regeneron, Repatha, Sanofi, cholesterol, praluent

A Delaware district court jury has ruled in favour of Amgen in an ongoing dispute around patents for cholesterol-lowering drugs …

News

NICE changes mind on Amgen’s cholesterol drug

February 8, 2016
Manufacturing and Production, Sales and Marketing Amgen, NICE, Repatha

NICE has changed its mind on Amgen’s cholesterol-busting drug Repatha (evolocumab), and decided to recommend approval of the treatment in …

News

Amgen earns first Japanese nod for PCSK9 inhibitor

January 25, 2016
Sales and Marketing Amgen, Astellas, Japan, PCSK9 inhibitor, Repatha, evolocumab, high cholesterol

The Japanese Ministry of Health, Labour and Welfare has approved Amgen’s cholesterol-lowering medication Repatha, in a joint venture between Amgen …

News

NICE rejects Amgen’s Repatha in draft guidance

November 18, 2015
Research and Development, Sales and Marketing Amgen, NICE, Repatha, evolocumab, high cholesterol

NICE has published draft guidance rejecting Amgen’s Repatha as a treatment for people with high cholesterol.   

News

FDA approves Amgen’s cholesterol lowering drug

August 28, 2015
Medical Communications, Research and Development Amgen, FDA, Repatha, evolocumab

The FDA has endorsed Amgen’s cholesterol-lowering medication, Repatha, for the use in patients with high cholesterol. It follows Amgen’s successful …

News

Latest content

Novo Nordisk partners with UNICEF to prevent global childhood obesity

September 21, 2023

EC approves Menarini Group’s Orserdu for breast cancer treatment

September 21, 2023

Pharmanovia acquires CNS portfolio from Sanofi

September 20, 2023

Exscientia enters AI drug discovery collaboration with Merck KGaA

September 20, 2023

EC approves Pfizer’s Litfulo for adolescents and adults with alopecia

September 19, 2023